{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "regulatory-approval", "type": "clause", "offset": [180, 199]}, {"key": "as-amended", "type": "definition", "offset": [327, 337]}, {"key": "from-time-to-time", "type": "clause", "offset": [338, 355]}, {"key": "foreign-equivalent", "type": "definition", "offset": [365, 383]}], "size": 75, "snippet": "means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. \u00a7 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "samples": [{"hash": "7uWGVx1DHQa", "uri": "/contracts/7uWGVx1DHQa#phase-iii-study", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 33.7994537354, "published": true}, {"hash": "6RvUkLrUSPk", "uri": "/contracts/6RvUkLrUSPk#phase-iii-study", "label": "License Agreement (C4 Therapeutics, Inc.)", "score": 31.6913070679, "published": true}, {"hash": "5YduHGoMT7d", "uri": "/contracts/5YduHGoMT7d#phase-iii-study", "label": "Collaboration and License Agreement (C4 Therapeutics, Inc.)", "score": 31.6913070679, "published": true}], "hash": "18c763e374ea6f4c370e23437db68645", "id": 1}, {"snippet_links": [{"key": "and-safety", "type": "clause", "offset": [53, 63]}, {"key": "phase-ii-study", "type": "definition", "offset": [102, 116]}, {"key": "registration-of-the-product", "type": "clause", "offset": [330, 357]}], "size": 26, "snippet": "means any controlled study in humans of the efficacy and safety of a product which is conducted after Phase II Study has been completed and which is prospectively designed to demonstrate statistically whether the product is safe and effective for use in a particular indication and is usually intended to be sufficient to support registration of the Product.", "samples": [{"hash": "akniOI8leAQ", "uri": "/contracts/akniOI8leAQ#phase-iii-study", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "5gKBf1qgNUE", "uri": "/contracts/5gKBf1qgNUE#phase-iii-study", "label": "License Agreement", "score": 30.1263828278, "published": true}, {"hash": "fF229IChUop", "uri": "/contracts/fF229IChUop#phase-iii-study", "label": "Agreement and Plan of Merger (MeiraGTx Holdings PLC)", "score": 29.4052028656, "published": true}], "hash": "8c3ac61049e637b3fe93cfc99f67e9b0", "id": 2}, {"snippet_links": [{"key": "pivotal-clinical-study", "type": "definition", "offset": [19, 41]}, {"key": "regulatory-approval", "type": "clause", "offset": [226, 245]}], "size": 26, "snippet": "means a controlled pivotal clinical study of a Product that is prospectively designed to demonstrate statistically whether such Product is effective and safe for use in a particular indication in a manner sufficient to obtain Regulatory Approval to market such Product", "samples": [{"hash": "5QYW98yfg01", "uri": "/contracts/5QYW98yfg01#phase-iii-study", "label": "Development, Manufacturing and Supply Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 23.0807666779, "published": true}, {"hash": "dUwQmqpllRy", "uri": "/contracts/dUwQmqpllRy#phase-iii-study", "label": "Development, Manufacturing and Supply Agreement (Tekmira Pharmaceuticals Corp)", "score": 22.4182071686, "published": true}, {"hash": "f5n27JjLeQ7", "uri": "/contracts/f5n27JjLeQ7#phase-iii-study", "label": "Development, Manufacturing and Supply Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 22.1307315826, "published": true}], "hash": "9f028d545f5b7e11924060da904f5372", "id": 3}, {"snippet_links": [{"key": "large-scale", "type": "definition", "offset": [8, 19]}, {"key": "human-clinical-trial", "type": "definition", "offset": [20, 40]}, {"key": "the-requirements", "type": "clause", "offset": [75, 91]}, {"key": "as-amended", "type": "definition", "offset": [116, 126]}, {"key": "the-fda", "type": "clause", "offset": [162, 169]}, {"key": "phase-iv-study", "type": "definition", "offset": [191, 205]}], "size": 19, "snippet": "means a large scale human clinical trial in any country that would satisfy the requirements of 21 C.F.R. 312.21(c) (as amended) (whether or not such trial is for the FDA), but which is not a Phase IV Study.", "samples": [{"hash": "1N02hFiwTAq", "uri": "/contracts/1N02hFiwTAq#phase-iii-study", "label": "License Agreement (Zai Lab LTD)", "score": 28.6194381714, "published": true}, {"hash": "85ty2DnuFGi", "uri": "/contracts/85ty2DnuFGi#phase-iii-study", "label": "License Agreement (Zai Lab LTD)", "score": 28.4852848053, "published": true}, {"hash": "jxGFifK8dNk", "uri": "/contracts/jxGFifK8dNk#phase-iii-study", "label": "Collaboration and License Agreement (Ra Pharmaceuticals, Inc.)", "score": 27.7816562653, "published": true}], "hash": "45de63eeafb04077945f4bc2f43af2bd", "id": 4}, {"snippet_links": [{"key": "pivotal-clinical-study", "type": "definition", "offset": [8, 30]}, {"key": "clinical-development-candidate", "type": "definition", "offset": [90, 120]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [155, 174]}, {"key": "the-requirements", "type": "clause", "offset": [203, 219]}, {"key": "foreign-equivalent", "type": "definition", "offset": [252, 270]}, {"key": "with-respect-to", "type": "clause", "offset": [271, 286]}, {"key": "cardiovascular-indication", "type": "definition", "offset": [341, 366]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [403, 421]}, {"key": "applications-for-regulatory-approval", "type": "clause", "offset": [465, 501]}, {"key": "regulatory-authorities", "type": "clause", "offset": [519, 541]}, {"key": "the-territory", "type": "clause", "offset": [558, 571]}], "size": 8, "snippet": "means a pivotal clinical study in human patients with a defined dose or set of doses of a Clinical Development Candidate that is designed to ascertain the safety and efficacy of (or to otherwise satisfy the requirements of 21 C.F.R. \u00a7 312.21(c) or its foreign equivalent with respect to) such Clinical Development Candidate for a particular Cardiovascular Indication, which Phase III Study is conducted for the purpose of enabling the preparation and submission of applications for Regulatory Approval to the competent regulatory authorities in a country of the Territory.", "samples": [{"hash": "d0XuHdeseKc", "uri": "/contracts/d0XuHdeseKc#phase-iii-study", "label": "Strategic Alliance Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}, {"hash": "8WQL5ppxoBO", "uri": "/contracts/8WQL5ppxoBO#phase-iii-study", "label": "Strategic Alliance Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}, {"hash": "35oasw6ClWA", "uri": "/contracts/35oasw6ClWA#phase-iii-study", "label": "Strategic Alliance Agreement (BTHC VI Inc)", "score": 21.0, "published": true}], "hash": "0bf28292bd158ea74cea5ddc84c6c647", "id": 5}, {"snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "and-safety", "type": "clause", "offset": [62, 72]}, {"key": "to-file", "type": "definition", "offset": [308, 315]}, {"key": "application-for-regulatory-approval", "type": "definition", "offset": [319, 354]}, {"key": "the-product", "type": "definition", "offset": [359, 370]}, {"key": "further-defined", "type": "clause", "offset": [375, 390]}, {"key": "outside-the-united-states", "type": "definition", "offset": [443, 468]}], "size": 7, "snippet": "means a study of a Licensed Product in humans of the efficacy and safety of such product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient (alone or together with one or more other such studies) to file an application for Regulatory Approval for the product, as further defined in 21 C.F.R. \u00a7 312.21(c) (or the equivalent thereof outside the United States).", "samples": [{"hash": "hWVAGZVVnqr", "uri": "/contracts/hWVAGZVVnqr#phase-iii-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 33.0082130432, "published": true}, {"hash": "1CzYHXEctyp", "uri": "/contracts/1CzYHXEctyp#phase-iii-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 32.8959617615, "published": true}, {"hash": "gb5lRg1Fw4l", "uri": "/contracts/gb5lRg1Fw4l#phase-iii-study", "label": "Sublicense Agreement (Akouos, Inc.)", "score": 31.4257354736, "published": true}], "hash": "893110b46b00870973e67eae019b8c5d", "id": 6}, {"snippet_links": [{"key": "phase-iii-clinical-trial", "type": "definition", "offset": [8, 32]}, {"key": "as-prescribed", "type": "definition", "offset": [33, 46]}, {"key": "fda-regulations", "type": "definition", "offset": [61, 76]}], "size": 6, "snippet": "means a Phase III clinical trial as prescribed by applicable FDA regulations, or corresponding regulations of any comparable entity.", "samples": [{"hash": "fvMI8zKYVhy", "uri": "/contracts/fvMI8zKYVhy#phase-iii-study", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "lsJTxHgnCWq", "uri": "/contracts/lsJTxHgnCWq#phase-iii-study", "label": "Collaboration Agreement (Xoma LTD /De/)", "score": 18.0, "published": true}, {"hash": "lEaqJi4ldYk", "uri": "/contracts/lEaqJi4ldYk#phase-iii-study", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "b1b094bee54d7b433619eb92f75ed6d9", "id": 7}, {"snippet_links": [{"key": "conduct-of", "type": "clause", "offset": [10, 20]}, {"key": "licensed-product", "type": "definition", "offset": [107, 123]}], "size": 6, "snippet": "means the conduct of a human study, as described in 21 C.F.R. \u00a7312.21(c) and its foreign equivalents, of a Licensed Product.", "samples": [{"hash": "9Bb8FvoZQxI", "uri": "/contracts/9Bb8FvoZQxI#phase-iii-study", "label": "Commercial License Agreement (Sage Therapeutics, Inc.)", "score": 34.5961685181, "published": true}, {"hash": "2MZaRbI19Z0", "uri": "/contracts/2MZaRbI19Z0#phase-iii-study", "label": "Commercial License Agreement (Sage Therapeutics, Inc.)", "score": 25.5147151947, "published": true}, {"hash": "hzMHOFdTPRx", "uri": "/contracts/hzMHOFdTPRx#phase-iii-study", "label": "Commercial License Agreement (Sage Therapeutics, Inc.)", "score": 25.4079399109, "published": true}], "hash": "9cc12426dfc826d41bcf9d3024d5733e", "id": 8}, {"snippet_links": [{"key": "pivotal-study", "type": "definition", "offset": [8, 21]}, {"key": "and-safety", "type": "clause", "offset": [48, 58]}, {"key": "to-file", "type": "definition", "offset": [235, 242]}, {"key": "regulatory-approval", "type": "clause", "offset": [267, 286]}, {"key": "the-product", "type": "definition", "offset": [297, 308]}, {"key": "further-defined", "type": "clause", "offset": [313, 328]}, {"key": "federal-regulation", "type": "definition", "offset": [332, 350]}], "size": 5, "snippet": "means a pivotal study in humans of the efficacy and safety of a Product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient to file an NDA or MAA to obtain regulatory approval to market the product, as further defined in Federal Regulation 21 C.F.R. \u00a7312.21(c) and its foreign equivalents.", "samples": [{"hash": "gyzlBedSSmC", "uri": "/contracts/gyzlBedSSmC#phase-iii-study", "label": "License Agreement (Kura Oncology, Inc.)", "score": 32.1485290527, "published": true}, {"hash": "kFlkWC9VYrg", "uri": "/contracts/kFlkWC9VYrg#phase-iii-study", "label": "License Agreement (Kura Oncology, Inc.)", "score": 26.4976043701, "published": true}, {"hash": "ayTU4oicRcS", "uri": "/contracts/ayTU4oicRcS#phase-iii-study", "label": "License Agreement (Kura Oncology, Inc.)", "score": 26.1909656525, "published": true}], "hash": "d88a4e48e10e24487d54e625def45b34", "id": 9}, {"snippet_links": [{"key": "in-respect-of", "type": "definition", "offset": [7, 20]}, {"key": "sublicensed-product", "type": "definition", "offset": [23, 42]}, {"key": "submission-and-approval-process", "type": "clause", "offset": [72, 103]}, {"key": "clinical-studies", "type": "definition", "offset": [122, 138]}, {"key": "additional-information", "type": "clause", "offset": [167, 189]}, {"key": "and-safety", "type": "clause", "offset": [210, 220]}, {"key": "overall-benefit", "type": "clause", "offset": [250, 265]}, {"key": "specifically-defined", "type": "clause", "offset": [305, 325]}, {"key": "rules-and-regulations", "type": "clause", "offset": [333, 354]}, {"key": "future-revisions", "type": "clause", "offset": [406, 422]}, {"key": "clinical-study", "type": "definition", "offset": [464, 478]}, {"key": "the-united-states", "type": "definition", "offset": [518, 535]}], "size": 5, "snippet": "means, in respect of a Sublicensed Product, (a) that portion of the FDA submission and approval process in which expanded clinical studies are conducted to gather the additional information about effectiveness and safety that is need to evaluate the overall benefit-risk relationship of a product as more specifically defined by the rules and regulations of the FDA, including 21 C.F.R. \u00a7 312.21(c) or any future revisions or substitutes thereof; or (b) a similar clinical study in any natural jurisdiction other than the United States.", "samples": [{"hash": "9cX0w1IduWP", "uri": "/contracts/9cX0w1IduWP#phase-iii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 32.9863090515, "published": true}, {"hash": "aMt9MeF5YxJ", "uri": "/contracts/aMt9MeF5YxJ#phase-iii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 32.225189209, "published": true}, {"hash": "kzMpucSa7YX", "uri": "/contracts/kzMpucSa7YX#phase-iii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 29.1389465332, "published": true}], "hash": "3104916406f0314a2fca223ea6a22ae8", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYcGhhc2UtaWlpLXN0dWR5IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 311, "snippet": "means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. \u00a7 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "title": "Phase III Study", "id": "phase-iii-study", "examples": [], "related": [["phase-ii-study", "Phase II Study", "Phase II Study"], ["phase-i-study", "Phase I Study", "Phase I Study"], ["phase-iii-trial", "Phase III Trial", "Phase III Trial"], ["phase-iii-clinical-study", "Phase III Clinical Study", "Phase III Clinical Study"], ["phase-iii-clinical-trial", "Phase III Clinical Trial", "Phase III Clinical Trial"]], "related_snippets": [], "updated": "2025-11-14T05:31:25+00:00"}, "json": true, "cursor": ""}}